Drug maker GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH) Thursday said it has begun a phase 2/3 clinical trial of Epidiolex for the treatment of child epilepsy in Dravet syndrome, following a "very encouraging" open-label trial. The Phase 2/3 trial will test the safety, tolerability, pharmacokinetic, and efficacy of Epidiolex. An additional phase 3 trial is expected begin in Q1 2015 in parallel with part two of the first phase 2/3 trial. Furthermore, two phase 3 clinical trials in Lennox-Gastaut syndrome will also be launched in Q1 2015. GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH) is trading within a 52-week range is $28.00 - $111.46.Lithia Motors Inc (NYSE:LAD) reported Q3 results, with earnings beating the Street by $0.01 and revenues in-line with the consensus of analysts polled by Capital IQ. Lithia Motors reported Q3 adjusted net income from continuing operations of $34.9 million, or $1.32 per diluted share, representing its highest adjusted net income ever recorded, and topping the consensus of $1.31 per share. Lithia Motors Inc (NYSE:LAD) reported adjusted net income from continuing operations of $29.6 million, or $1.13 per diluted share in the year-ago period. Revenues increased 21.3% to 1.3 billion, in-line with Street estimates of $1.3 billion.The company reaffirmed its FY14 guidance with EPS expected between $4.86 and $4.88 versus the consensus of $4.87, and annual sales of $5.2 billion-$5.4 billion compared to the consensus of $5.26 billion. For FY15, Lithia Motors also reaffirmed its outlook with EPS of $5.60-$5.80 below the consensus of $5.98 and revenues of $7.4 billion-$7.6 billion in-line with the Street estimate of $7.55 billion. The company also said it will distribute a quarterly dividend of $0.16 per share, unchanged relative to the previous dividend announcement. The dividend will be payable on December 5 to shareholders of record on November 21.Elizabeth Arden, Inc. (NASDAQ:RDEN) reported that for Q1 ended Sept. 30, 2014, loss was narrower than expected, while revenue missed analysts' expectation; it reiterated its guidance for fiscal 2015 and 2016. The beauty products company posted Q1 net loss of $45.8 million or $1.54 loss per share, compared with the prior-year period's net income of $1.7 million or $0.06 per share. Adjusted net loss was $12.94 million or $0.43 loss per share, ex one-time items, versus net income of $6.75 million or $0.22 per share in the same quarter the previous year. Adjusted revenue was $273.1 million, down 20.5% from $343.61 million in the same quarter last year. Analysts polled by Capital IQ were expecting a loss per share of $0.53 on revenues of $275.07 million. Elizabeth Arden, Inc. (NASDAQ:RDEN) said it continues to expect a modest improvement in adjusted earnings for fiscal 2015 over the prior year with continued improvement in fiscal 2016. Shares are trading with a 52-week range of $14.65 - $40.40.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
